Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health for technologies relating to autologous TIL adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers; cooperative research and development agreement with the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient's TIL, as well as for the treatment of cervical, head and neck, lung, bladder, and breast cancer; and manufacturing services agreement with PharmaCell B.V and WuXi Apptech, Inc. to manufacture, package, ship, and handle quality assurance and quality control of clinical trials for TIL products. In addition, it has collaboration and license agreements with Medimmune, Inc. to conduct clinical and preclinical research in immuno-oncology; H. Lee Moffitt Cancer Center and Research Institute to research and develop adoptive TIL cell therapy; PolyBioCept, AB to develop, manufacture, market, and genetically engineer TIL; and the University of Texas M.D. Anderson Cancer Center for multi-arm clinical trials for TIL therapy. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IOVA
CUSIPN/A
Phone650-260-7120
Debt
Debt-to-Equity RatioN/A
Current Ratio20.61
Quick Ratio20.61
Price-To-Earnings
Trailing P/E Ratio-9.45
Forward P/E Ratio-10.47
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.71 per share
Price / Book7.78
Profitability
EPS (Most Recent Fiscal Year)($1.41)
Net Income$-92,060,000.00
Net MarginsN/A
Return on Equity-53.45%
Return on Assets-50.55%
Miscellaneous
Employees63
Outstanding Shares89,640,000
Iovance Biotherapeutics (NASDAQ:IOVA) Frequently Asked Questions
What is Iovance Biotherapeutics' stock symbol?
Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."
How were Iovance Biotherapeutics' earnings last quarter?
Iovance Biotherapeutics Inc (NASDAQ:IOVA) posted its quarterly earnings results on Thursday, May, 10th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.29) by $0.03. View Iovance Biotherapeutics' Earnings History.
When is Iovance Biotherapeutics' next earnings date?
What price target have analysts set for IOVA?
8 brokerages have issued 1 year target prices for Iovance Biotherapeutics' shares. Their forecasts range from $17.50 to $31.00. On average, they anticipate Iovance Biotherapeutics' share price to reach $22.3571 in the next year. View Analyst Ratings for Iovance Biotherapeutics.
What are Wall Street analysts saying about Iovance Biotherapeutics stock?
Here are some recent quotes from research analysts about Iovance Biotherapeutics stock:
- 1. According to Zacks Investment Research, "Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies Inc., is based in SAN CARLOS, United States. " (1/20/2018)
- 2. Cowen Inc analysts commented, "IOVA reported that the first patient in LN-145’s Phase II cervical cancer study has been." (8/16/2017)
Who are some of Iovance Biotherapeutics' key competitors?
Some companies that are related to Iovance Biotherapeutics include Ablynx (ABLYF), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Crispr Therapeutics (CRSP), argenx (ARGX), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Regenxbio (RGNX), Atara Biotherapeutics (ATRA), Repligen (RGEN), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Momenta Pharmaceuticals (MNTA), Acceleron Pharma (XLRN) and Denali Therapeutics (DNLI).
Who are Iovance Biotherapeutics' key executives?
Iovance Biotherapeutics' management team includes the folowing people:
- Dr. Maria Fardis, CEO, Pres & Director (Age 50)
- Dr. Michael T. Lotze M.D., Chief Scientific Officer and VP of R&D (Age 66)
- Dr. Elma S. Hawkins Ph.D., MBA, Advisor to the Board (Age 61)
- Mr. Timothy E. Morris, CFO & Principal Accounting Officer (Age 56)
- Dr. Frederick G. Vogt Ph.D., Esq., Gen. Counsel
Has Iovance Biotherapeutics been receiving favorable news coverage?
Headlines about IOVA stock have trended somewhat positive this week, according to Accern. The research group rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Iovance Biotherapeutics earned a news impact score of 0.17 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 45.71 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Iovance Biotherapeutics' major shareholders?
Iovance Biotherapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include venBio Select Advisor LLC (9.01%), BlackRock Inc. (6.45%), Franklin Resources Inc. (5.93%), Farallon Capital Management LLC (4.63%), Victory Capital Management Inc. (2.55%) and Northern Trust Corp (0.97%). View Institutional Ownership Trends for Iovance Biotherapeutics.
Which major investors are selling Iovance Biotherapeutics stock?
IOVA stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Prosight Management LP, Millennium Management LLC, Citigroup Inc., Barclays PLC, Balter Liquid Alternatives LLC, Allianz Asset Management GmbH and Allianz Asset Management GmbH. View Insider Buying and Selling for Iovance Biotherapeutics.
Which major investors are buying Iovance Biotherapeutics stock?
IOVA stock was purchased by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Farallon Capital Management LLC, BlackRock Inc., Artal Group S.A., Franklin Resources Inc., PointState Capital LP, Victory Capital Management Inc. and Northern Trust Corp. View Insider Buying and Selling for Iovance Biotherapeutics.
How do I buy shares of Iovance Biotherapeutics?
Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Iovance Biotherapeutics' stock price today?
One share of IOVA stock can currently be purchased for approximately $13.27.
How big of a company is Iovance Biotherapeutics?
Iovance Biotherapeutics has a market capitalization of $1.22 billion. The biotechnology company earns $-92,060,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis. Iovance Biotherapeutics employs 63 workers across the globe.
How can I contact Iovance Biotherapeutics?
Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at 650-260-7120 or via email at [email protected]
MarketBeat Community Rating for Iovance Biotherapeutics (IOVA)
MarketBeat's community ratings are surveys of what our community members think about Iovance Biotherapeutics and other stocks. Vote "Outperform" if you believe IOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
